NCT00984360

Study of Naltrexone for Methamphetamine Addiction

A Pilot Trial of Naltrexone for Methamphetamine Addiction - Role of the A118G SNP

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: California Pacific Medical Center Research Institute · Academic / Other
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether methamphetamine-dependent individuals will use less methamphetamine when treated with naltrexone. The study will also investigate whether individuals with the mu opioid receptor gene variant A118G will use less methamphetamine than individuals without A118G.

Conditions

• Methamphetamine Dependence

Interventions

Type	Name	Description
DRUG	Naltrexone	380mg extended-release, given once by intramuscular gluteal injection

Timeline

• Start date: 2009-09-01
• Primary completion: 2011-07-01
• Completion: 2012-09-01
• First posted: 2009-09-25
• Last updated: 2013-05-31

Locations

1 site across 1 country: United States